Literature DB >> 14579142

ACE-inhibitors-induced metabolic acidosis in a child with nephrotic syndrome.

Irene Bruno1, Marco Pennesi, Federico Marchetti.   

Abstract

In recent years there has been an increase in the use of ACE inhibitors in the paediatric population. We describe a case of hyperchloraemic metabolic acidosis with hypoaldosteronism in a 4-year-old boy with nephrotic syndrome who was receiving ACE inhibitors.

Entities:  

Mesh：

Substances：

Year:  2003        PMID： 14579142     DOI： 10.1007/s00467-003-1282-2

Source DB:  PubMed          Journal:  Pediatr Nephrol        ISSN： 0931-041X            Impact factor:   3.714


  7 in total

1.  Angiotensin converting enzyme inhibition in non-diabetic nephropathy with non-nephrotic proteinuria.

Authors:  M Pennesi; G Torre
Journal:  Pediatr Nephrol       Date:  2000-05       Impact factor: 3.714

2.  Reversible hyperkalemia at the initiation of ACE inhibitors in a young diabetic patient with latent hyporeninemic hypoaldosteronism.

Authors:  F Bonnet; C H Thivolet
Journal:  Diabetes Care       Date:  1996-07       Impact factor: 19.112

3.  Captopril-induced metabolic acidosis with hyperkalemia.

Authors:  T Sakemi; N Ohchi; T Sanai; O Rikitake; T Maeda
Journal:  Am J Nephrol       Date:  1988       Impact factor: 3.754

4.  Transtubular potassium concentration gradient: a useful test to estimate renal aldosterone bio-activity in infants and children.

Authors:  J Rodríguez-Soriano; M Ubetagoyena; A Vallo
Journal:  Pediatr Nephrol       Date:  1990-03       Impact factor: 3.714

5.  Randomised placebo-controlled trial of effect of ramipril on decline in glomerular filtration rate and risk of terminal renal failure in proteinuric, non-diabetic nephropathy. The GISEN Group (Gruppo Italiano di Studi Epidemiologici in Nefrologia)

Authors: 
Journal:  Lancet       Date:  1997-06-28       Impact factor: 79.321

6.  Hyperkalemia in azotemic patients during angiotensin-converting enzyme inhibition and aldosterone reduction with captopril.

Authors:  S C Textor; E L Bravo; F M Fouad; R C Tarazi
Journal:  Am J Med       Date:  1982-11       Impact factor: 4.965

7.  Acid-base and endocrine effects of aldosterone and angiotensin II inhibition in metabolic acidosis in human patients.

Authors:  A Henger; P Tutt; W F Riesen; H N Hulter; R Krapf
Journal:  J Lab Clin Med       Date:  2000-11
  7 in total
  1 in total

1.  Safety monitoring of drugs receiving pediatric marketing exclusivity.

Authors:  P Brian Smith; Daniel K Benjamin; M Dianne Murphy; Rosemary Johann-Liang; Solomon Iyasu; Barbara Gould; Robert M Califf; Jennifer S Li; William Rodriguez
Journal:  Pediatrics       Date:  2008-09       Impact factor: 7.124
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.